So I think, I think there is now more and more opportunity to continue to move from, you know, what do we do to how do we actually execute this as a core component of our overall strategy, and how must we do this in order to continue to operate, you know, globy-- global and multi-regional clinical trials.

I'd like to build on a few of the points that j- both Jan and Tanaya brought up.

When we talk about the ability to ensure we have the right representation, we are basing that on the reason we do science, the reason we must do good science with good trial design.

So while we would all like the guidance to be in every regulatory organization, we would like clarity on expectations both for delivering a trial as a sponsor, executing a trial as a site.

The regulatory agencies aren't all going to do it the same way.

They may, like the FDA did, put it in place, remove it, put it in place, remove it, right? We need to go ahead and depend on our sponsors to be delivering the right information about the clinical trial, about the medicine they're studying and the true prevalence and science behind that so we can design the trials and execute them with the right populations.

If we all start with the right science in mind, we will do the best job for patients everywhere, whether it's ethnicity, it's genetics, it is country, right? We will focus on-- By focusing on the science, we will deliver the best outcomes with the highest efficacy possible for patients.

Yeah.